Completed PHASE2 INTERVENTIONAL 2-arm NCT00169559

Dyslipidemia Study Investigating The Increase In Good Cholesterol

A Multi-center, Three-staged, Randomized, Parallel Group, Sequential, Double-blind, fenofibrate-and Placebo-controlled Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma HDLc and TG of Eight Weeks Treatment With 1µg to 20µg Daily Doses of GW590735 in Otherwise Healthy Subjects With Low HDLc, Mildly to Moderately Elevated TG, and Normal LDLc

Sponsor: GlaxoSmithKline

Conditions Dyslipidaemias

Interventions GW590735 fenofibrate

Updated 7 times since 2017 Last updated: Oct 18, 2012 Started: Nov 30, 2003 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00169559, this PHASE2 trial focuses on Dyslipidaemias and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Auburn, United States , Beverly Hills, United States , Birmingham, United States , Bristol, United States , Brooklyn Center, United States , Bryan, United States , Calgary, Canada , Cincinnati, United States , Conroe, United States and 36 more locations